



### **Transfer of the Medicea liquidity agreement**

**Lyon and New York, January 14<sup>th</sup>, 2019** – The Medicea Group (Euronext Growth Paris: FR0004178572-ALMED ; OTCQX Best Market –MRNTF), pioneering the transformation of spinal surgery through artificial Intelligence, predictive modeling and patient specific implants with its UNiD™ ASI (Adaptive Spine Intelligence) proprietary software platform, services and technologies, announces having terminated the liquidity agreement previously entrusted to Louis Capital Market, with effect from January 14<sup>th</sup>, 2019 and transferred it to Kepler Cheuvreux.

Upon termination of the liquidity agreement entrusted to Louis Capital, the following assets were credited to the liquidity account: 4,756 securities and 8,878 € in cash, against 3,563 securities and 11,001 € in cash initially allocated to the implementation of the initial liquidity agreement with Louis Capital Market.

Medicea entrusts Kepler Cheuvreux to act as Liquidity Provider, from January 15<sup>th</sup>, 2019 with tacit renewals for successive terms of twelve (12) months thereafter.

Kepler Cheuvreux shall be appointed to buy and sell shares for Medicea on Euronext Paris. The terms and conditions will be set forth under a liquidity agreement, with ordinary shares Euronext Paris- Code ISIN FR0004178572.

The liquidity agreement will comply with AMF Decision n° 2018-01 dated 2nd July 2018.

The resources allocated to the implementation of the liquidity agreement entrusted to Kepler Cheuvreux are as follows:

- 4,756 shares
- 8,878 € in cash

**About Medicrea ([www.medicrea.com](http://www.medicrea.com))**

Through the lens of predictive medicine, Medicrea leverages its proprietary software analysis tools with big data and machine learning technologies supported by an expansive collection of clinical and scientific data. The Company is well-placed to streamline the efficiency of spinal care, reduce procedural complications and limit time spent in the operating room.

Operating in a \$10 billion marketplace, Medicrea is a Small and Medium sized Enterprise (SME) with 200 employees worldwide, which includes 50 who are based in the U.S. The Company has an ultra-modern manufacturing facility in Lyon, France housing the development and production of 3D- printed titanium patient-specific implants.

For further information, please visit: [Medicrea.com](http://Medicrea.com).

**Connect with Medicrea**

[FACEBOOK](#) | [INSTAGRAM](#) | [TWITTER](#) | [WEBSITE](#) | [YOUTUBE](#)

**Medicrea**

Denys SOURNAC  
Founder, Chairman and CEO  
dsournac@medicrea.com

Fabrice KILFIGER  
Chief Financial Officer  
fkilfiger@medicrea.com  
Tel: +33 (0)4 72 01 87 87

**Medicrea is listed on  
EURONEXT Growth Paris**

**ISIN: FR 0004178572**

**Ticker: ALMED**

**LEI: 969500BR1CPTYMTJBA37**



**Medicrea is traded on**

**OTCQX Best Market**

**Ticker: MRNTF**

**MRNTY | MRNTF**

**TRADED ON**

